HC Wainwright Issues Positive Outlook for XENE Earnings

Key Points

• HC Wainwright raised its earnings outlook for Xenon Pharmaceuticals, forecasting a Q3 2026 loss of $1.07 per share versus its prior $1.10 estimate and a FY2026 loss of $4.48. The firm maintained a Buy rating and a $74 price target.
• Xenon reported a quarterly loss of $1.11 per share, beating analyst expectations for a $1.16 loss by $0.05. The stock was trading at $64.23, up 1.4%, with a consensus rating of Buy and an average price target of $77.13.
• Despite improved long-term forecasts suggesting the company is moving toward breakeven, Xenon remains unprofitable through the end of the decade. Institutional investors own approximately 95.45% of its shares, while two directors recently sold stock.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2026 EPS estimates for Xenon Pharmaceuticals in a report released on Friday, August 7th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will earn ($1.07) per share for the quarter, up from their prior estimate of ($1.10). HC Wainwright has a "Buy" rating and a $74.00 price objective on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($4.92) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals' Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($4.48) EPS, Q2 2027 earnings at ($1.21) EPS, Q3 2027 earnings at ($1.22) EPS, Q4 2027 earnings at ($1.24) EPS, FY2027 earnings at ($4.88) EPS, FY2028 earnings at ($3.89) EPS, FY2029 earnings at ($2.23) EPS and FY2030 earnings at ($0.18) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same period in the prior year, the business posted ($1.07) EPS.

A number of other brokerages have also recently issued reports on XENE. Wall Street Zen upgraded shares of Xenon Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, August 1st. Royal Bank Of Canada decreased their target price on Xenon Pharmaceuticals from $82.00 to $81.00 and set an "outperform" rating for the company in a research report on Friday. Needham & Company LLC decreased their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a "buy" rating for the company in a report on Friday, May 8th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an "overweight" rating in a research note on Wednesday, May 27th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $77.13.

Xenon Pharmaceuticals Trading Up 1.4%

NASDAQ XENE opened at $64.23 on Tuesday. The company has a fifty day simple moving average of $60.45 and a 200 day simple moving average of $54.46. Xenon Pharmaceuticals has a 12-month low of $32.78 and a 12-month high of $72.66. The company has a market cap of $6.21 billion, a P/E ratio of -13.55 and a beta of 0.62.

Insider Activity at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 1,322 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the transaction, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gillian Cannon sold 1,190 shares of the business's stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the transaction, the director directly owned 1,455 shares of the company's stock, valued at approximately $77,318.70. This represents a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.91% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in XENE. Cinctive Capital Management LP boosted its stake in Xenon Pharmaceuticals by 1.1% during the fourth quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company's stock valued at $1,045,000 after buying an additional 263 shares during the period. State of Wyoming boosted its position in shares of Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company's stock valued at $67,000 after acquiring an additional 350 shares during the last quarter. Quarry LP boosted its position in shares of Xenon Pharmaceuticals by 25.0% during the 3rd quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company's stock valued at $100,000 after acquiring an additional 500 shares during the last quarter. Altfest L J & Co. Inc. grew its holdings in shares of Xenon Pharmaceuticals by 6.5% during the fourth quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company's stock worth $369,000 after purchasing an additional 501 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Xenon Pharmaceuticals by 0.7% during the first quarter. Royal Bank of Canada now owns 90,387 shares of the biopharmaceutical company's stock worth $5,255,000 after purchasing an additional 630 shares in the last quarter. Institutional investors own 95.45% of the company's stock.

Key Headlines Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright improved its EPS outlook for Q3 2026 to a loss of $1.07 from $1.10, Q4 2026 to a loss of $1.13 from $1.16, and full-year 2026 to a loss of $4.48 from $4.52. The firm also raised its FY2027, FY2028, FY2029 and FY2030 forecasts, indicating expectations for a faster reduction in losses and improving long-term financial performance.
• Positive Sentiment: The FY2030 estimate was upgraded to a loss of $0.18 per share from $0.37, while FY2027 improved to a loss of $4.88 from $5.00. Although Xenon remains unprofitable, the revisions suggest it is moving closer to breakeven over time, which can support investor sentiment for a development-stage biopharmaceutical company.
• Neutral Sentiment: HC Wainwright’s estimates imply continued substantial losses through 2029, including projected losses of $4.88 per share in FY2027 and $3.89 in FY2028. The stock’s valuation therefore remains dependent on clinical and commercial execution rather than current earnings.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company's research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon's scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company's pipeline comprises multiple preclinical and clinical programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source